3种抗组胺药治疗慢性特发性荨麻疹的临床研究

目的:评价第2代抗组胺药咪唑斯汀、西替利嗪、氯雷他定治疗慢性特发性荨麻疹的疗效和安全性。方法:采用随机开放平行对照的方法,对96例慢性特发性荨麻疹患者进行随机分组,分别予以咪唑斯汀10mg、西替利嗪10mg、氯雷他定10mg,均每日1次口服,观察治疗第14天、第28天的临床疗效及停药1周后的复发率。结果:三者治疗慢性特发性荨麻疹第14天和第28天的有效率分别为:咪唑斯汀组90.0%和96.7%,西替利嗪组85.3%和94.2%,氯雷他定组90.6%和93.8%,三者之间差异无显著性(P>0.05)。停药1周后的复发率,咪唑斯汀组为40.0%,西替利嗪组为35.3%,氯雷他定组为28.1%。整个试验过程中均无明显严重不良反应出现。结论:咪唑斯汀、西替利嗪和氯雷他定治疗慢性特发性荨麻疹临床疗效好,安全性高,在改善临床症状及控制复发方面各有所长。

Clinical research of three antihistamines in the treatment of chronic idiopathic urticaria

Objective:To evaluate the efficacy and safety of three second-generation antihistamines in the treatment of chronic idio pathic urticaria.Methods:A randomized,open-label,parallel comparative clinical trial was conducted in96pa-tients.They were divid ed into three groups,treated with daily mizolastine10mg,cetirizine10mg and loratatine10mg re-spectively.The therapeutic re sults were observed on14th day and28th day.The recurrent rates were also recorded one week after discontinuation of the treatment.Results:There was similar clinical efficiency among the three drugs.The effi-cient rates of mizolastine,cetirizine and loratatine were90.0%,85.3%,90.6%at14th day and96.7%,94.2%,93.8%at28th day,respectively.But there was no significantly statistical difference among the three groups(P>0.05).The recurrent rates of mizolastine,cetirizine and loratatine were40.0%,35.3%and28.1%,respectively.No obvious and severe side-effects ap peared during the entire trial.Conclusions:All the three antihistamines have high clinical efficacy and safe ty in the treatment of chronic idiopathic ur ticaria.In some aspects,one drug is superior to the other two in improving clini cal syn-drome and controlling recurrence.